ADCT
ADC Therapeutics SA
Price Chart
Latest Quote
$1.03
-0.29 (-21.97%)
Current Price
| Previous Close | $1.32 |
| Open | $1.36 |
| Day High | $1.38 |
| Day Low | $1.02 |
| Volume | 7,184,492 |
Stock Information
| Shares Outstanding | 127.19M |
| Total Debt | $436.26M |
| Cash Equivalents | $231.01M |
| Revenue | $79.17M |
| Net Income | $-136.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $131.01M |
| EPS (TTM) | $-0.97 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $336.26M |
| Sales | $79.17M |
| Income | $-136.99M |
| Book/sh | $-1.70 |
| Cash/sh | $1.82 |
| Employees | 188 |
Financial Ratios
| Quick Ratio | 3.88 |
| Current Ratio | 4.09 |
Returns & Margins
| ROA | -22.73% |
| Gross Margin | -26.33% |
| Operating Margin | -121.07% |
| Profit Margin | -173.02% |
Ownership
| Insider Ownership | 13.44% |
| Institutional Ownership | 67.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.69 |
| P/S | 1.65 |
| P/B | -0.61 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.75 |
Technical Indicators
| SMA20 | $3.13 |
| SMA50 | $3.58 |
| SMA200 | $3.81 |
| RSI | 13.25 |
| ATR | 0.2932 |
| Shares Float | 100.41M |
| Short Float | 5.33% |
| Short Ratio | 4.53 |
| Volatility | 1.77 |
| Rel Volume | 3.89 |
Performance History
| Week | -69.71% |
| Month | -73.32% |
| Quarter | -74.94% |
| 6 Months | -73.92% |
| YTD | -70.74% |
| Year | -69.16% |
| 3 Years | -56.17% |
| 5 Years | -95.24% |
| 10 Years | -96.57% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.03 | 7,184,492 |
| 2026-06-04 | $1.32 | 12,639,800 |
| 2026-06-03 | $3.08 | 1,648,300 |
| 2026-06-02 | $3.17 | 796,800 |
| 2026-06-01 | $3.40 | 620,400 |
| 2026-05-29 | $3.40 | 689,900 |
| 2026-05-28 | $3.45 | 454,500 |
| 2026-05-27 | $3.43 | 601,700 |
| 2026-05-26 | $3.51 | 793,900 |
| 2026-05-22 | $3.39 | 648,500 |
| 2026-05-21 | $3.40 | 862,200 |
| 2026-05-20 | $3.24 | 664,900 |
| 2026-05-19 | $3.14 | 885,000 |
| 2026-05-18 | $3.17 | 1,434,600 |
| 2026-05-15 | $3.25 | 1,103,300 |
| 2026-05-14 | $3.36 | 904,000 |
| 2026-05-13 | $3.48 | 1,048,100 |
| 2026-05-12 | $3.43 | 1,201,400 |
| 2026-05-11 | $3.48 | 1,100,200 |
| 2026-05-08 | $3.50 | 1,632,300 |
| 2026-05-07 | $3.75 | 1,408,400 |
| 2026-05-06 | $3.86 | 2,630,400 |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
đ° Latest News
Top Midday Decliners
MT Newswires âĸ 2026-06-04T18:25:24ZADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
Zacks âĸ 2026-06-04T14:43:00Z
An ADC specialist sinks on safety concerns for blood cancer drug
BioPharma Dive âĸ 2026-06-04T09:27:02Z
Big Pharmaâs 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
24/7 Wall St. âĸ 2026-05-14T13:20:55Z
ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-05-04T23:05:16Z
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-04T20:44:37Z
ADCT Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-04T20:23:31Z
ADC Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-04T13:39:55Z
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-04T12:35:02Z
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Zacks âĸ 2026-05-01T13:40:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,798,000 | $5,949,000 | $2,529,000 | $3,301,000 |
| Cost Of Revenue | $5,798,000 | $5,949,000 | $2,529,000 | $3,301,000 |
| Total Revenue | $81,357,000 | $70,837,000 | $69,558,000 | $209,908,000 |
| Operating Revenue | $81,357,000 | $70,837,000 | $69,558,000 | $209,908,000 |
| Expenses | ||||
| Interest Expense | $51,633,000 | $50,211,000 | $46,325,000 | $36,731,000 |
| Total Expenses | $188,564,000 | $200,428,000 | $234,609,000 | $332,895,000 |
| Other Income Expense | $8,422,000 | $11,394,000 | $5,417,000 | $10,333,000 |
| Other Non Operating Income Expenses | $22,212,000 | $11,474,000 | $5,469,000 | $26,906,000 |
| Net Non Operating Interest Income Expense | $-42,823,000 | $-37,939,000 | $-35,785,000 | $-34,163,000 |
| Interest Expense Non Operating | $51,633,000 | $50,211,000 | $46,325,000 | $36,731,000 |
| Operating Expense | $182,766,000 | $194,479,000 | $232,080,000 | $329,594,000 |
| Selling And Marketing Expense | $19,485,000 | $21,442,000 | $33,006,000 | $35,752,000 |
| General And Administrative Expense | $60,448,000 | $64,467,000 | $72,882,000 | $107,742,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Net Interest Income | $-42,823,000 | $-37,939,000 | $-35,785,000 | $-34,163,000 |
| Interest Income | $8,810,000 | $12,272,000 | $10,540,000 | $2,568,000 |
| Normalized Income | $-131,728,900 | $-157,782,800 | $-240,011,920 | $-144,035,330 |
| Net Income From Continuing And Discontinued Operation | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Total Operating Income As Reported | $-121,499,000 | $-130,654,000 | $-165,986,000 | $-123,344,000 |
| Net Income Common Stockholders | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Net Income | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Net Income Including Noncontrolling Interests | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Net Income Continuous Operations | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $-1,544,000 | $-5,528,000 | $-10,084,000 |
| Pretax Income | $-141,608,000 | $-156,136,000 | $-195,419,000 | $-146,817,000 |
| Special Income Charges | $-13,120,000 | $0 | $0 | $-42,114,000 |
| Interest Income Non Operating | $8,810,000 | $12,272,000 | $10,540,000 | $2,568,000 |
| Operating Income | $-107,207,000 | $-129,591,000 | $-165,051,000 | $-122,987,000 |
| Gross Profit | $75,559,000 | $64,888,000 | $67,029,000 | $206,607,000 |
| Earnings From Equity Interest | - | - | - | $-10,084,000 |
| Per Share | ||||
| Diluted EPS | - | $-1.62 | $-2.94 | $-1.99 |
| Basic EPS | - | $-1.62 | $-2.94 | $-1.99 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,895,900 | $-16,800 | $-10,920 | $-3,480,330 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-74,309,000 | $-102,569,000 | $-145,775,000 | $-91,125,000 |
| Total Unusual Items | $-13,790,000 | $-80,000 | $-52,000 | $-16,573,000 |
| Total Unusual Items Excluding Goodwill | $-13,790,000 | $-80,000 | $-52,000 | $-16,573,000 |
| Reconciled Depreciation | $1,876,000 | $3,276,000 | $3,267,000 | $2,388,000 |
| EBITDA (Bullshit earnings) | $-88,099,000 | $-102,649,000 | $-145,827,000 | $-107,698,000 |
| EBIT | $-89,975,000 | $-105,925,000 | $-149,094,000 | $-110,086,000 |
| Diluted NI Availto Com Stockholders | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Tax Provision | $1,015,000 | $166,000 | $39,106,000 | $227,000 |
| Other Special Charges | $1,333,000 | - | - | $42,114,000 |
| Impairment Of Capital Assets | $5,755,000 | - | - | - |
| Restructuring And Mergern Acquisition | $6,032,000 | - | - | - |
| Gain On Sale Of Security | $-670,000 | $-80,000 | $-52,000 | $25,541,000 |
| Other Taxes | $-1,172,000 | $-1,063,000 | $-935,000 | $-357,000 |
| Research And Development | $104,005,000 | $109,633,000 | $127,127,000 | $186,457,000 |
| Selling General And Administration | $79,933,000 | $85,909,000 | $105,888,000 | $143,494,000 |
| Other Gand A | $13,913,000 | $17,683,000 | $20,542,000 | $25,985,000 |
| Salaries And Wages | $46,535,000 | $46,784,000 | $52,340,000 | $81,757,000 |
| Diluted Average Shares | - | $97,159,966 | $81,712,166 | $78,152,964 |
| Basic Average Shares | - | $97,159,966 | $81,712,166 | $78,152,964 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-185,834,000 | $-202,642,000 | $-148,249,000 | $79,451,000 |
| Total Assets | $323,150,000 | $321,980,000 | $354,782,000 | $490,859,000 |
| Total Non Current Assets | $16,815,000 | $30,726,000 | $18,491,000 | $55,879,000 |
| Other Non Current Assets | $15,518,000 | $17,297,000 | $711,000 | $902,000 |
| Current Assets | $306,335,000 | $291,254,000 | $336,291,000 | $434,980,000 |
| Other Current Assets | $6,084,000 | $9,450,000 | $5,990,000 | $23,495,000 |
| Prepaid Assets | $5,612,000 | $8,370,000 | $10,344,000 | $23,296,000 |
| Inventory | $4,184,000 | $2,251,000 | $16,177,000 | $12,073,000 |
| Receivables | $29,117,000 | $20,316,000 | $25,182,000 | $72,971,000 |
| Accounts Receivable | $29,117,000 | $20,316,000 | $25,182,000 | $72,971,000 |
| Cash Cash Equivalents And Short Term Investments | $261,338,000 | $250,867,000 | $278,598,000 | $326,441,000 |
| Cash And Cash Equivalents | $261,338,000 | $250,867,000 | $278,598,000 | $326,441,000 |
| Non Current Deferred Assets | - | - | $0 | $37,104,000 |
| Non Current Deferred Taxes Assets | - | - | $0 | $37,104,000 |
| Goodwill And Other Intangible Assets | - | - | - | $14,360,000 |
| Other Intangible Assets | - | - | - | $14,360,000 |
| Other Receivables | - | - | - | $3,361,000 |
| Taxes Receivable | - | - | - | $763,000 |
| Accrued Interest Receivable | - | - | - | $619,000 |
| Debt | ||||
| Total Debt | $117,024,000 | $122,998,000 | $124,377,000 | $117,375,000 |
| Long Term Debt And Capital Lease Obligation | $113,486,000 | $121,627,000 | $122,910,000 | $116,278,000 |
| Long Term Debt | $112,452,000 | $113,632,000 | $112,730,000 | $109,714,000 |
| Current Debt And Capital Lease Obligation | $3,538,000 | $1,371,000 | $1,467,000 | $1,097,000 |
| Current Debt | $3,000,000 | - | - | $12,474,000 |
| Other Current Borrowings | $3,000,000 | - | - | $12,474,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $508,984,000 | $524,622,000 | $503,031,000 | $411,408,000 |
| Total Non Current Liabilities Net Minority Interest | $438,821,000 | $444,153,000 | $435,361,000 | $329,469,000 |
| Other Non Current Liabilities | $2,810,000 | $2,433,000 | $8,879,000 | $838,000 |
| Non Current Deferred Liabilities | $322,525,000 | $320,093,000 | $303,572,000 | $212,353,000 |
| Current Liabilities | $70,163,000 | $80,469,000 | $67,670,000 | $81,939,000 |
| Other Current Liabilities | $23,130,000 | $26,946,000 | $13,039,000 | $16,558,000 |
| Payables And Accrued Expenses | $43,495,000 | $52,152,000 | $53,164,000 | $64,284,000 |
| Payables | $9,175,000 | $18,029,000 | $15,569,000 | $12,351,000 |
| Accounts Payable | $9,175,000 | $18,029,000 | $15,569,000 | $12,351,000 |
| Derivative Product Liabilities | - | - | - | $1,788,000 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-185,834,000 | $-202,642,000 | $-148,249,000 | $79,451,000 |
| Total Equity Gross Minority Interest | $-185,834,000 | $-202,642,000 | $-148,249,000 | $79,451,000 |
| Stockholders Equity | $-185,834,000 | $-202,642,000 | $-148,249,000 | $79,451,000 |
| Gains Losses Not Affecting Retained Earnings | $-517,000 | $-1,421,000 | $-93,000 | $1,823,000 |
| Other Equity Adjustments | $-517,000 | $-1,421,000 | $-93,000 | $1,823,000 |
| Retained Earnings | $-1,635,941,000 | $-1,493,318,000 | $-1,335,472,000 | $-1,095,419,000 |
| Long Term Equity Investment | - | $0 | $1,647,000 | $7,613,000 |
| Other | ||||
| Treasury Shares Number | $2,561,248 | $2,744,974 | $6,748,809 | $8,399,419 |
| Ordinary Shares Number | $125,748,762 | $98,861,402 | $82,293,137 | $80,642,527 |
| Share Issued | $128,310,010 | $101,606,376 | $89,041,946 | $89,041,946 |
| Tangible Book Value | $-185,834,000 | $-202,642,000 | $-148,249,000 | $79,451,000 |
| Invested Capital | $-70,382,000 | $-89,010,000 | $-35,519,000 | $189,165,000 |
| Working Capital | $236,172,000 | $210,785,000 | $268,621,000 | $353,041,000 |
| Capital Lease Obligations | $1,572,000 | $9,366,000 | $11,647,000 | $7,661,000 |
| Total Capitalization | $-73,382,000 | $-89,010,000 | $-35,519,000 | $189,165,000 |
| Treasury Stock | $205,000 | $220,000 | $541,000 | $679,000 |
| Additional Paid In Capital | $1,439,749,000 | $1,283,892,000 | $1,180,545,000 | $1,166,414,000 |
| Capital Stock | $11,080,000 | $8,425,000 | $7,312,000 | $7,312,000 |
| Common Stock | $11,080,000 | $8,425,000 | $7,312,000 | $7,312,000 |
| Long Term Capital Lease Obligation | $1,034,000 | $7,995,000 | $10,180,000 | $6,564,000 |
| Current Capital Lease Obligation | $538,000 | $1,371,000 | $1,467,000 | $1,097,000 |
| Current Accrued Expenses | $34,320,000 | $34,123,000 | $37,595,000 | $51,933,000 |
| Net PPE | $1,297,000 | $13,429,000 | $16,133,000 | $10,260,000 |
| Accumulated Depreciation | $-1,381,000 | $-5,320,000 | $-4,275,000 | $-3,408,000 |
| Gross PPE | $2,678,000 | $18,749,000 | $20,408,000 | $13,668,000 |
| Leases | $225,000 | $3,873,000 | $3,953,000 | $2,082,000 |
| Other Properties | $1,297,000 | $12,769,000 | $14,163,000 | $9,437,000 |
| Machinery Furniture Equipment | $1,156,000 | $2,107,000 | $2,292,000 | $2,149,000 |
| Properties | $0 | $0 | $0 | $0 |
| Investments And Advances | - | $0 | $1,647,000 | $7,613,000 |
| Investmentsin Joint Venturesat Cost | - | $0 | $1,647,000 | $7,613,000 |
| Finished Goods | - | $49,000 | $82,000 | $16,000 |
| Work In Process | - | $18,338,000 | $16,095,000 | $12,057,000 |
| Foreign Currency Translation Adjustments | - | - | - | $-356,000 |
| Employee Benefits | - | - | - | $0 |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | - | $0 |
| Non Current Deferred Revenue | - | - | - | $23,539,000 |
| Construction In Progress | - | - | - | $0 |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-141,438,000 | $-124,702,000 | $-121,902,000 | $-138,998,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-141,174,000 | $-123,835,000 | $-118,686,000 | $-138,311,000 |
| Cash Flow From Continuing Operating Activities | $-141,174,000 | $-123,835,000 | $-118,686,000 | $-138,311,000 |
| Operating Gains Losses | - | $1,544,000 | $4,319,000 | $40,694,000 |
| Investing Activities | ||||
| Capital Expenditure | $-264,000 | $-867,000 | $-3,216,000 | $-687,000 |
| Investing Cash Flow | $395,000 | $-867,000 | $-3,216,000 | $-687,000 |
| Cash Flow From Continuing Investing Activities | $395,000 | $-867,000 | $-3,216,000 | $-687,000 |
| Net Other Investing Changes | - | - | - | $-210,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $86,282,000 | $60,506,000 | $0 | $6,130,000 |
| Financing Cash Flow | $150,945,000 | $97,054,000 | $73,875,000 | $-897,000 |
| Cash Flow From Continuing Financing Activities | $150,945,000 | $97,054,000 | $73,875,000 | $-897,000 |
| Net Other Financing Charges | $-1,514,000 | $-1,163,000 | $73,102,000 | $-122,624,000 |
| Net Common Stock Issuance | $86,282,000 | $60,506,000 | $0 | $6,130,000 |
| Common Stock Issuance | $86,282,000 | $60,506,000 | $0 | $6,130,000 |
| Repurchase Of Capital Stock | - | - | - | $-221,000 |
| Other | ||||
| Interest Paid Supplemental Data | $14,467,000 | $15,702,000 | $15,387,000 | $10,178,000 |
| End Cash Position | $261,338,000 | $250,867,000 | $278,598,000 | $326,441,000 |
| Beginning Cash Position | $250,867,000 | $278,598,000 | $326,441,000 | $466,544,000 |
| Effect Of Exchange Rate Changes | $305,000 | $-83,000 | $184,000 | $-208,000 |
| Changes In Cash | $10,166,000 | $-27,648,000 | $-48,027,000 | $-139,895,000 |
| Proceeds From Stock Option Exercised | $66,177,000 | $37,711,000 | $773,000 | $0 |
| Net PPE Purchase And Sale | $395,000 | $-867,000 | $-3,216,000 | $-687,000 |
| Sale Of PPE | $659,000 | $0 | - | - |
| Purchase Of PPE | $-264,000 | $-867,000 | $-3,216,000 | $-687,000 |
| Change In Working Capital | $-25,355,000 | $3,826,000 | $44,271,000 | $-48,725,000 |
| Change In Other Current Liabilities | $-2,914,000 | $-8,883,000 | $5,675,000 | $-1,203,000 |
| Change In Other Current Assets | $-46,000 | $-456,000 | $7,489,000 | $-11,674,000 |
| Change In Payables And Accrued Expense | $-16,458,000 | $13,602,000 | $-10,970,000 | $16,556,000 |
| Change In Accrued Expense | $-7,420,000 | $11,140,000 | $-14,143,000 | $16,246,000 |
| Change In Payable | $-9,038,000 | $2,462,000 | $3,173,000 | $310,000 |
| Change In Account Payable | $-9,038,000 | $2,462,000 | $3,173,000 | $310,000 |
| Change In Prepaid Assets | $5,233,000 | $-1,480,000 | - | - |
| Change In Inventory | $-2,381,000 | $-3,728,000 | $-5,712,000 | $-9,651,000 |
| Change In Receivables | $-8,789,000 | $4,771,000 | $47,789,000 | $-42,753,000 |
| Changes In Account Receivables | $-8,789,000 | $4,771,000 | $47,789,000 | $-42,753,000 |
| Other Non Cash Items | $9,044,000 | $17,279,000 | $17,303,000 | $-25,406,000 |
| Stock Based Compensation | $6,905,000 | $6,568,000 | $13,495,000 | $49,322,000 |
| Asset Impairment Charge | $8,979,000 | $1,518,000 | $1,608,000 | $2,165,000 |
| Depreciation Amortization Depletion | $1,876,000 | $3,276,000 | $3,267,000 | $2,388,000 |
| Depreciation And Amortization | $1,876,000 | $3,276,000 | $3,267,000 | $2,388,000 |
| Depreciation | $1,876,000 | $3,276,000 | $3,267,000 | $2,388,000 |
| Earnings Losses From Equity Investments | $0 | $1,544,000 | $5,528,000 | $10,084,000 |
| Net Income From Continuing Operations | $-142,623,000 | $-157,846,000 | $-240,053,000 | $-157,128,000 |
| Deferred Tax | - | $0 | $37,104,000 | $-1,621,000 |
| Deferred Income Tax | - | $0 | $37,104,000 | $-1,621,000 |
| Pension And Employee Benefit Expense | - | $-186,000 | $-712,000 | $0 |
| Gain Loss On Investment Securities | - | $-296,000 | $-497,000 | $-11,504,000 |
| Issuance Of Debt | - | - | $0 | $115,597,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $115,597,000 |
| Net Long Term Debt Issuance | - | - | $0 | $115,597,000 |
| Long Term Debt Issuance | - | - | $0 | $115,597,000 |
| Repayment Of Debt | - | - | - | $-1,011,000 |
| Common Stock Payments | - | - | - | $-221,000 |
| Long Term Debt Payments | - | - | - | $-1,011,000 |
| Net Intangibles Purchase And Sale | - | - | - | $-1,721,000 |
| Purchase Of Intangibles | - | - | - | $-1,721,000 |
| Taxes Refund Paid | - | - | - | $-13,473,000 |
| Interest Received Cfo | - | - | - | $2,139,000 |
| Interest Paid Cfo | - | - | - | $-10,370,000 |
| Change In Other Working Capital | - | - | - | $1,848,000 |
| Amortization Cash Flow | - | - | - | $118,000 |
| Amortization Of Intangibles | - | - | - | $118,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $-107,000 |
Fetched: 2026-05-30